Capital DailyCapital Daily
Markets · Investing · Business
Capital DailyCapital Daily
Finance

How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?

The Danish company developed the most lucrative new drug the world had ever seen. Then America’s Eli Lilly outmaneuvered it and took control of the diet-drug market.

How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?

Published August 5, 2026 · Category: Finance

Overview

The Danish company developed the most lucrative new drug the world had ever seen. Then America’s Eli Lilly outmaneuvered it and took control of the diet-drug market.

Source

Originally published at www.marketwatch.com.

Related Articles

CD
Capital Daily Newsroom

Capital Daily covers markets, crypto and commodities for Asia & the Middle East — tier-1 desk research, AI-driven analysis, institutional-grade data. Tip our newsroom: [email protected]

Email the newsroom →
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.